Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix Stock Surges 79.7 Percent on Launch of Avian Flu Array

NEW YORK,Oct. 26 (GenomeWeb News) - Shares in CombiMatrix were up 79.7 percent, or $1.10, at $2.48 in mid-afternoon trading after the company launched an influenza DNA microarray.

 

According to CombiMatrix, the microarray can identify H5N1 bird flu and influenza A strains as well as provide information on mutations and unknown strains.

 

CombiMatrix's Influenza Microarray is included in its CatalogArray product line. It can detect and accurately type flu strains using a protocol that requires fewer than four hours, the company said. It is also designed to work on samples from humans, birds, pigs, horses, dogs, and other animals.

 

CombiMatrix is offering the system as a tool or as a service to researchers, and is also developing it as a field-deployable biodetector using electrochemical techniques.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more